Evidence‐based hidradenitis suppurativa guidelines – and now all together please

Jemec, Gregor B. E.

doi:10.1111/bjd.17734

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an article published recently in the British Journal of Dermatology , Jemec [83] highlights the difficulties encountered in developing guidelines, as new evidence in the field of HS research necessitates regular review and reevaluation of treatment recommendations. There are several targeted agents for HS treatment in the drug development pipeline, further underscoring the importance of timely and comprehensive updates [84].…”

Section: Discussionmentioning

confidence: 99%

A Comparison of International Management Guidelines for Hidradenitis Suppurativa

et al. 2019

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that imparts a significant burden on patients and presents a management challenge for healthcare providers. As attention to this debilitating condition has grown over recent years, our understanding of HS pathogenesis and optimal treatment approaches continues to evolve. Nine HS treatment guidelines developed by various expert organizations have been published, encompassing therapeutic modalities ranging from topical agents to systemic therapies to procedural interventions. These guidelines demonstrate significant overlap in treatment recommendations and have all been published within the last 5 years. Therefore, we aim to compare and synthesize the recommendations of international HS treatment guidelines and to encourage inter-organizational communication for the development of consensus or staggered publication of recommendations for HS management.

show abstract

Section: Discussionmentioning

confidence: 99%

A Comparison of International Management Guidelines for Hidradenitis Suppurativa

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Recently, the difficulties in developing unified international guidelines were highlighted by Jemec 45 . He stressed that although countries working to develop guidelines is commendable, this is happening in parallel, which means that the literature reviewed at the time is similar.…”

Section: Treatment Optionsmentioning

confidence: 99%

“…He stressed that although countries working to develop guidelines is commendable, this is happening in parallel, which means that the literature reviewed at the time is similar. With the vast and rapid amount of growing knowledge in HS, it would be more beneficial if countries worked together to create a rotating publication schedule to constantly update guidelines for HS patients and providers based on available evidence 45 .…”

Section: Treatment Optionsmentioning

confidence: 99%

The most recent advances in understanding and managing hidradenitis suppurativa

2020

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients’ growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.

show abstract

“…In a recent BJD commentary, Gregor Jemec pointed out that efforts of CPG development teams are frequently repeated by several teams at more or less the same time, in several countries or regions . The duplication of effort often leads to similar findings, resulting in research waste.…”

mentioning

confidence: 99%

Publication of national dermatology guidelines as a Research Letter in the BJD : can less ever be enough?

Zuuren

Arents²,

Flohr

et al. 2020

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Evidence‐based hidradenitis suppurativa guidelines – and now all together please

Abstract: Linked Article: Ingram et al. Br J Dermatol 2019; 180:1009–1017.

Cited by 3 publications

References 9 publications

A Comparison of International Management Guidelines for Hidradenitis Suppurativa

A Comparison of International Management Guidelines for Hidradenitis Suppurativa

The most recent advances in understanding and managing hidradenitis suppurativa

Publication of national dermatology guidelines as a Research Letter in the BJD : can less ever be enough?

Contact Info

Product

Resources

About